Reported in today's Business Report is news that Africa's largest drug maker Aspen Pharmacare has purchased four GlaxoSmithKline (GSK) products, according to group chief executive Stephen Saad. Aspen's international subsidiary, Aspen Global, paid £170 million (R2.7 billion) for the intellectual property rights to Eltroxin, Imuran, Lanoxin and Zyloric for all major markets except the US and Japan. For the full report click here.
African intellectual property law, practice and policies. This weblog provides news, information and comment on IP law, practice and business deals right across Africa. Ce blog propose des actualités, informations, et commentaires sur la législation et la pratique en matière de propriété intellectuelle et de droit des contrats d'affaires en Afrique. For some insight into the origins of this blog click here.
Tuesday, 1 July 2008
Aspen's IP deal
Reported in today's Business Report is news that Africa's largest drug maker Aspen Pharmacare has purchased four GlaxoSmithKline (GSK) products, according to group chief executive Stephen Saad. Aspen's international subsidiary, Aspen Global, paid £170 million (R2.7 billion) for the intellectual property rights to Eltroxin, Imuran, Lanoxin and Zyloric for all major markets except the US and Japan. For the full report click here.
Labels:
aspen
| Reactions: |
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment